Ruvidar Effective in the Treatment of Herpes
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Ruvidar TM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 ('HSV-1") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model.
Herpes Simplex Virus ('HSV'), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable. 1
There are two main types of HSV: 1
Type 1 ('HSV-1") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1.
Type 2 ('HSV-2") spreads by sexual contact and causes herpes in the genital region of an individual.
An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes. 1
The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033. 2
The market growth can be attributed to the growing concerns over HSV infection, including, oral and genital herpes. Moreover, the infection is highly contagious, spreading via saliva, vaginal secretion or semen and is acquired unknowingly. These factors highlight the increasing need for treatment throughout the projected period. 3
North America accounted for the largest market share of 37.1% in 2024, which can be attributed to higher consumption of branded herpes drugs, escalating healthcare expenditure, increasing launch of generics and favorable reimbursement policies. 2
The HSV-1 lifecycle begins upon contact with mucosal surfaces and it is in this niche, where the virus actively replicates inducing local lesion formation. The virus then enters local sensory nerve endings and migrates back to neuronal cell bodies in the peripheral nervous system. It is in this location where the virus enters into a latent, non-replicative stage until later reactivation. 4
Despite longstanding attempts at therapy and prevention, HSV remains among the most prevalent human infectious viral pathogens; therefore, it's imperative to keep HSV from replicating by implementing advanced vaccines and more effective drugs to combat and defeat this pervasive disease.
In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0.
TM (1%).
Figure 2. Abreva treatment of HSV-1 infected cutaneous lesions
To view an enhanced version of this graphic, please visit:
Acyclovir (1%) Treatment
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/2786/245623_3.jpg ]
Figure 3. Acyclovir (1%) treatment of HSV-1 infected cutaneous lesions
Cannot view this image? Visit:
Ruvidar TM (1%) Treatment
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/2786/245623_4.jpg ]
Figure 4. Ruvidar TM (1%) treatment of HSV-1 infected cutaneous lesions
Cannot view this image? Visit:
The results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model.
Pavel Kaspler, Ph.D., research scientist, Theralase®, who conducted the preclinical study stated, " I am extremely impressed with the efficacy of the Ruvidar TM to successfully heal the HSV-1 lesions in an animal model versus common standard of care treatments, currently available, such as Abreva and Acyclovir. My next set of experiments will be to increase the number of daily applications of Abreva, Acyclovir and Ruvidar TM (from once daily to 5 times daily) and increase the dosage of Acyclovir and Ruvidar TM (1 to 5%) to see how this affects the healing time of HSV-1 lesions. It is my hope that my preclinical research leads to the development of a clinical treatment to aid the multitude of individuals suffering from cold sores.'
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase® stated, " Based on the chemical properties of Ruvidar TM, I am not surprised that it has had such a dramatic effect on the inactivation of HSV-1 lesions in this animal model. It is well established in the literature that the HSV-1 virus' glycoproteins (glycans - gB and gC) are negatively charged, as is the Heparan Sulphate ('HS') receptors on a cell's surface (preferred binding site of the virus on a cell). This provides a novel mechanism (based on controlled electrostatic repulsion) that addresses how viruses balance between optimized viral attachment to target cells and efficient egress of progeny virus. 5,6 On the other hand, Ruvidar TM is positively charged. 7 This allows Ruvidar TM the unique ability to be able to bind to and block the glycoproteins on HSV-1, preventing binding to host cells, as well as on the HS cell surface receptors preventing the efficient egress of progeny virus. This leads to an inability of the virus to replicate, allowing accelerated healing of cold sore lesions. '
Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer, Theralase® stated, " As always, I am in awe of the ability of Ruvidar TM to effectively destroy cancer cells, as well as efficiently inactivate bacteria and viruses. Based on the success of this latest preclinical research, Theralase®, pending funding in 2025, will commence formulation of Ruvidar TM into topical form, complete GLP toxicology and commence a Phase I/II adaptive clinical study to demonstrate the safety and efficacy of Ruvidar TM in the accelerated healing of cold sore lesions in humans. '
1 2 3 Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
Herpes Simplex Virus Treatment Market Size, Share & Trends Analysis Report By Type (HSV-1, HSV-2), By Drug (Acyclovir, Valacyclovir, Famciclovir), By Vaccine (Simplirix, Others), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
4 Roizman B, Knipe DM, Whitley R. Herpes Simplex Viruses. 6th ed. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. pp. 1823-1897.
5 Transforms of Cell Surface Glycoproteins Charge Influences Tumor Cell Metastasis via Atypically Inhibiting Epithelial-Mesenchymal Transition Including Matrix Metalloproteinases and Cell Junctions. Mingzhe Wang et al. Bioconjugate Chemistry. Vol. 34. Issue 8. July 2023
6 Olofsson S, Bally M, Trybala E, Bergström T. Structure and Role of O-Linked Glycans in Viral Envelope Proteins. Annu Rev Virol. 2023 Sep 29;10(1):283-304. doi: 10.1146/annurev-virology-111821-121007. Epub 2023 Jul 6. PMID: 37285578.
7
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements:
This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
416.699.LASE (5273)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
8 hours ago
- CNBC
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
For well over a decade, Grace Hamilton, 27, experienced hair loss, heavy periods, infrequent menstrual cycles, mental health issues and difficulty losing weight without knowing why. It wasn't until 2021 when she was diagnosed with polycystic ovary syndrome, or PCOS, a hormonal disorder common among women of reproductive age. After she saw limited improvements from birth control, diet and exercise, Hamilton joined a trial in 2024 examining a GLP-1 drug in PCOS patients. By October, she received her first weekly dose of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes shot Ozempic. She said some results were almost immediate: after months without a cycle, her period resumed within two weeks of starting the drug. After 10 months on the treatment, Hamilton lost 50 pounds, saw hair regrowth and reported significant improvements in depression and anxiety "I'm so glad that I stuck with it because it was just clear as day that it was the missing link for me," said Hamilton, who works at a nonprofit in Arvada, Colorado, adding that she maintained diet and exercise while on the drug. She is just one of several women who have reported improvements in symptoms of PCOS after using GLP-1s, a growing class of obesity and diabetes treatments that have drawn massive patient demand and investor buzz over the last few years. Treating PCOS is among several new but unapproved potential uses of the blockbuster drugs beyond promoting weight loss and regulating blood sugar. PCOS, which is frequently underdiagnosed, affects an estimated 5 million to 6 million women of reproductive age in the U.S., according to some estimates. The condition is typically characterized by higher levels of testosterone and other hormones usually associated with men called androgens, which can leads to symptoms such as irregular and painful periods, excess hair growth and acne. PCOS is the most common cause of infertility. The condition is strongly linked to metabolic issues, as an estimated 35% to 80% of patients experience insulin resistance. That means the pancreas pumps out more insulin to keep blood sugar in check, and high insulin levels can promote weight gain and disrupt hormone balance. A significant share of women with PCOS have obesity or Type 2 diabetes. Yet there's no standard PCOS treatment. Current options like birth control, lifestyle changes and the diabetes drug Metformin may only help with certain symptoms, which could differ depending on the patient. But some health experts see promise in GLP-1s, particularly given their effect on improving weight loss and insulin sensitivity. "The unmet need is massive," said Dr. Melanie Cree, a pediatric endocrinologist at Children's Hospital Colorado. "Primary therapies used for PCOS symptoms haven't changed in nearly 50 years." Cree has been studying the effect of GLP-1s in adolescents with PCOS for more than 10 years. She previously studied the oral form of semaglutide and has an ongoing clinical trial on the injectable version, which is what Hamilton participated in for 10 months. But her studies are still small in comparison to drugmakers' previous clinical trials on GLP-1s with thousands of patients. Not all of the women who have so far completed Cree's ongoing study lost significant weight, demonstrating that not everyone may respond to GLP-1s. Novo Nordisk and rival Eli Lilly have been studying their GLP-1s as potential treatments for other chronic conditions like fatty liver disease, but not PCOS. Cree said that's because the Food and Drug Administration has not established specific "endpoints" or goals drugs must meet in clinical trials to demonstrate how effective they are for PCOS. In a statement, a Novo Nordisk spokesperson said the company welcomes "independent research investigating the safety, efficacy and clinical utility of our products, including semaglutide." Eli Lilly did not immediately respond to a request for comment. Conducting longer and larger trials to better understand the effect of GLP-1s on PCOS symptoms is crucial, said Sasha Ottey, executive director of the advocacy group PCOS Challenge. It is still unclear if GLP-1s can help address or resolve all PCOS symptoms, or whether the effect differs depending on a patient's age or the specific drug, Ottey said. She added that certain patients may not lose weight on GLP-1s, and others may not need to shed pounds. Meanwhile, insurance coverage for GLP-1s is a barrier for some PCOS patients, who are often eligible for approved uses of the drugs. Most plans cover GLP-1s for diabetes, but not for obesity or unapproved uses. The drugs can cost roughly $1,000 per month before insurance. Still, Eli Lilly and Novo Nordisk offer significant discounts on their drugs to some patients who pay for it out-of-pocket. More research is needed to fully understand why GLP-1s may help some PCOS patients, but Cree said their effect on symptoms appears to be largely indirect. She said a key finding in several previous studies motivated her to start studying GLP-1s: In adults with PCOS, losing as little as 5% of body weight can improve insulin sensitivity. That makes the body respond better to insulin, so it doesn't need to produce as much of it to manage blood sugar. That lowers insulin levels, which Cree and some researchers believe causes the ovaries to produce less testosterone and, as a result, can help reduce symptoms such as irregular periods, acne and excess hair growth. "One of the questions was, what other methods do we have to improve insulin sensitivity?" Cree said. She noted that other recommended treatments for PCOS symptoms, such as food changes, increasing exercise and the diabetes drug Metformin, are based on that goal. GLP-1s such as semaglutide improve insulin sensitivity and reduce appetite through several mechanisms. That includes slowing how quickly food leaves the stomach, prompting the pancreas to release insulin when blood sugar is high and suppressing the release of a hormone that raises blood sugar. The weight loss caused by GLP-1s further helps improve insulin sensitivity. Early results from Cree's ongoing study support the idea that GLP-1s may lower testosterone. The trial, which began in 2023, follows girls and women ages 12 to 35 with obesity and PCOS who are on or off Metformin. The study is designed to administer semaglutide to patients for 10 months, and examine their weight loss, metabolic changes and improvements in reproductive function. Cree hopes the trial will answer whether GLP-1s can improve ovulation in women with PCOS. Many women with PCOS don't ovulate regularly, which can lead to irregular periods and difficulty getting pregnant. Cree has initial data on 11 women who completed the 10 months on semaglutide and were not on Metformin. She said eight of them lost more than 10% of their body weight and saw a reduction in their testosterone levels. Five out of the eight patients had their testosterone levels reach "normal ranges," Cree said. Meanwhile, six out of the eight patients reported more regular periods. Cree said her trial will eventually have data from 40 women, but she is still enrolling patients in the group that takes Metformin. She said it will likely take two years before she publishes the first results from the study, which will focus on the differences in outcomes between kids and adults who only received semaglutide. She said comparing the groups is crucial because hormones that control growth are released during puberty, which could change how kids respond to GLP-1s. Not all women with PCOS will benefit from taking a GLP-1. Cree said in her trial, three patients who completed 10 months on semaglutide did not lose at least 10% of their body weight. One of those women did not lose weight at all, she said. Cree said that's consistent with previous studies on GLP-1s in adults with obesity. Despite the promise of GLP-1s in improving symptoms, more research is also needed on PCOS itself, said Dr. Karen Tang, an OB-GYN and founder of Thrive Gynecology. She said some people can experience hallmark symptoms of the condition, such as facial hair and acne, even though they have normal levels of testosterone. "There's still a lot that's very much unknown about PCOS and exactly how the disease kind of works," Tang told CNBC. Anecdotal evidence suggests GLP-1s may address more than just weight issues for people with PCOS. In a recent survey of 1,700 people by the birth control app Natural Cycles, 64% of women with PCOS who took a GLP-1 reported more predictable periods, and 20% said their bleeding days were shorter. Some patients with PCOS may also lose more weight on GLP-1s than those without the condition, said Dr. Kerry Krauss, an OB/GYN and medical director at Natural Cycles, who has PCOS herself. Research needs to confirm those benefits, but she said it gives hope to many PCOS patients who are frustrated with common treatments for the condition. Those options typically target just one aspect of PCOS, such as reducing androgen levels with certain types of birth control. Tang added that diet and exercise alone often fall short of addressing symptoms: "A lot of people can exercise very aggressively and regularly or watch what they eat and still struggle with hormone imbalances, weight, and blood sugar." That was the case for Haley Sipes, a 31-year-old mother of three based in Western Kentucky who experienced PCOS symptoms for years without a diagnosis. In 2022, before being diagnosed, she lost 75 pounds over 10 months through diet and exercise alone. Her progress stalled in late 2022 despite an intense diet and exercise regimen, and her weight began to fluctuate in 2023. By mid-2024, she had regained about 30 pounds. Sipes sought help from her primary care provider and underwent blood work, which revealed she had a hormonal imbalance. Initial efforts to regulate her hormones with progesterone and testosterone had a limited effect. Further bloodwork diagnosed Sipes with PCOS and insulin resistance, which she views as the root cause of her weight loss struggles. She recalled bloating, fatigue, low energy, and water retention during earlier efforts to lose weight. Despite her history of painful, irregular periods and ovarian cysts since age 10, her providers never mentioned PCOS as a possible diagnosis. In September 2024, her doctor prescribed Zepbound. Her insurance covered it due to her BMI and prediabetes status. Sipes said she noticed changes within the first month: her food cravings quieted, her inflammation decreased, she experienced less joint pain, and her period became less painful and occurred more regularly. Sipes added that she has not had ovarian cysts since starting Zepbound. After around eight months on the medication, she lost more than 60 pounds. Sipes said those results significantly improved her emotional health. "All the symptoms and being overweight might not seem like big things, but when you have 20 little things that are constantly nagging you, then you're going to be in a bad mood sometimes," Sipes said. "I'm just a better version of myself when I'm not controlled by food thoughts and hormonal issues that cause mood swings," she continued. "My life does feel so much more enjoyable." Sipes plans to continue taking Zepbound to maintain her results, possibly at lower doses. She noted that more research is needed on whether PCOS symptoms can fully resolve. Insurance coverage is currently the biggest hurdle preventing PCOS patients from accessing GLP-1s, said Dr. Alyssa Dominguez, an endocrinologist with Keck School of Medicine at the University of Southern California. She said many PCOS patients are eligible to use GLP-1s for their approved uses based on BMI or related conditions, but may not have coverage. More than one-third of employers now cover GLP-1s for both weight loss and diabetes, while 55% only cover them for diabetes, according to a recent survey from the International Foundation of Employee Benefit Plans. In April, President Donald Trump rejected a Biden administration plan that would have required Medicare and Medicaid to cover obesity drugs. Some patients, like 34-year-old California mom Nabeelah Karim, have turned to other options. Karim was diagnosed with PCOS at 19 and took birth control on and off until giving birth in 2021. She said she struggled with hair loss, irregular periods, debilitating cramps, facial hair growth, severe water retention and mood swings. Karim said her period symptoms worsened after she gave birth, and in late 2023, she began what would be a painful five-month-long period. Doctors suggested that she lose weight, take painkillers or return to birth control. While Karim lost some weight through diet and exercise, she was eventually prescribed Eli Lilly's diabetes drug Mounjaro through the digital health startup Noom in April 2024. Her long period stopped and symptoms eased within days, and she began to lose more weight over time. "It had solved all the problems that I had experienced for years up until that point," Karim said. But her insurance plan never formally approved or denied coverage of Mounjaro, forcing her to pay its more than $1,000 per month out-of-pocket price. She eventually found a third-party compounding pharmacy that accepted her prescription, allowing her to buy a cheaper but unapproved version of the drug. Karim used that compounded version for six months and continued to experience weight loss and improvements to her PCOS symptoms. During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. They can also be produced on a case-by-case basis when it's medically necessary for a patient, such as when they can't swallow a pill or are allergic to a specific ingredient. But Novo Nordisk, Eli Lilly and some health experts have pushed back – and in some cases, taken legal action – against the practice, largely because the FDA does not approve compounded drugs. The FDA has declared U.S. shortages of both companies' drugs over. "When people ask about how safe compounded drugs are, the answer I typically give is I don't know," said Dominguez from USC's School of Medicine. She said that's unlike branded drugs, which have clearly defined risks and benefits proven in clinical trials. Hamilton, the 27-year-old patient who took a GLP-1 for PCOS symptoms, has never taken a compounded GLP-1. She is currently appealing her insurer's denial of semaglutide now that she has completed Cree's trial. "My whole life has been an inability to access care for my medical condition, and I'm tired of that," she said. "If somebody would have been able to provide 11-year-old Grace with this drug, that would have saved me."
Tom's Guide
11 hours ago
- Tom's Guide
I drank lemon balm tea every day for a week to see if it could reduce stress and aid digestion — here's my verdict
If you've been around me for more than 90 seconds, you'll know that the last word anyone would use to describe me is 'calm.' If you're around me with my toddler and dog in tow, you'd probably recommend I take up yoga, or wonder how one person gets through the day surrounded by such chaos. With this in mind, when I heard about the viral TikTok trend of drinking lemon balm tea to reduce stress and anxiety, I decided to give it a try for a week to see if I noticed any difference. Read on to find out what happened. According to recent studies, lemon balm tea offers several benefits for both mental and physical well-being. Lemon balm is a fragrant herb from the mint family, characterized by its lemon-scented leaves. It has been found to have antiviral properties, as well as being anti-inflammatory. One of the most well-researched benefits of consuming lemon balm is its calming effect on the nervous system. This is said to reduce feelings of stress, anxiety, and nervousness. As well as helping you feel less stressed, lemon balm is thought to boost your mood and improve cognitive function and memory. Lemon balm is often used as a natural remedy for conditions such as insomnia and sleep disturbances, due to its calming properties. It's often paired with ingredients like camomile to help you fall asleep more easily and improve your overall sleep quality. Lemon balm is sometimes used in natural remedies for colic thanks to its ability to soothe digestive issues. It can also help with bloating, indigestion, gas and stomach cramps. Lemon balm is also used in topical ointments that treat cold sores (HSV-1) thanks to its antiviral properties. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. As a reminder, while lemon balm tea is considered safe to drink for most people, you should always check with your doctor if you're on regular medication, or if you're pregnant or breastfeeding. Possible side effects associated with the consumption of lemon balm include headaches, nausea, vomiting and diarrhea. If you notice any of these side effects, stop taking lemon balm immediately. Was lemon balm tea the secret to feeling calmer? Here's what happened when I committed to drinking lemon balm tea every day for a week. Before popping the kettle on, I had to find lemon balm to drink. I keep a fresh mint plant in my garden, so I assumed I'd be able to buy a lemon balm plant in my local supermarket, and that I'd be able to stew the leaves in my teapot. Unfortunately, it was a little trickier to find, so I ended up having to buy dried leaves on the internet instead. I also found a 'happy' tea blend which contained lemon balm, turmeric and apple. In my first few days, I committed to sipping lemon balm at my desk. I usually drink peppermint tea, and the lemon balm tasted very similar. Plus, this article gave me more of an excuse to step away from my desk for a tea break. While I wasn't immediately feeling much calmer, I did need to pee more. As well as being full of antioxidants, drinking more tea means more water. It was convenient that I was doing this challenge during a heatwave here in the UK, so sipping on a couple of cups of tea during the day helped me drink more water and avoid dehydration. Plus, another benefit is that lemon balm tea is naturally caffeine-free. I found I was drinking less coffee, which is always a good thing, as too much leaves me feeling even more anxious. By the end of the week, I was fully on board with lemon balm tea and could quite easily make the switch from peppermint. I liked the taste and switched to my 'happy tea' blend when I wanted something a little punchier. I didn't notice any differences in my digestion, but I don't often suffer from bloating or indigestion. While I'm not sure my nervous system felt any calmer, I did find that the ritual of stepping away from my desk and making a tea, or sitting down with one after getting my son to bed, helped me carve out moments of calm during a very busy day. I'm going to continue sipping lemon balm tea, so maybe by the end of the month, I'll be an Instagram-perfect mum, finding calm in the chaos. Until then, I'll keep taking deep breaths when my toddler throws his dinner at the kitchen wall. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Associated Press
a day ago
- Associated Press
Luxury Aesthetics Reimagined: Beauty Factory LV Launches Cutting-Edge Morpheus8 RF Microneedling and Signature Sculpting Treatments
Las Vegas, Nevada--(Newsfile Corp. - July 18, 2025) - Beauty Factory LV, the premier destination for high-end aesthetics in Las Vegas, has officially expanded its service offerings with the launch of Morpheus8 Advanced RF Microneedling, along with a curated suite of bespoke injectables and sculpting treatments. This new chapter signals a commitment to providing next-generation, non-surgical solutions for clients seeking luxury results with minimal downtime. [ This image cannot be displayed. Please visit the source: ] Figure 1: Beauty Factory To view an enhanced version of this graphic, please visit: A Revolution in Skin Rejuvenation At the forefront of the launch is the Morpheus8 Advanced RF Microneedling treatment—a breakthrough technology that blends deep microneedling with targeted radiofrequency energy. This premium, minimally invasive service is designed to lift, tighten, and rejuvenate the skin, making it ideal for contouring the jawline, smoothing fine lines, and revitalizing aging or dull complexions. 'This is not your average facial,' said Maise Pastrano, a representative for Beauty Factory LV. 'With Morpheus8, our clients can achieve sculpted, youthful results with clinical precision—without going under the knife.' Injectable Artistry with Natural Elegance Complementing the Morpheus8 treatment, Beauty Factory LV now offers precision dermal fillers focused on facial contouring—particularly the chin and lips. These bespoke injectables are tailored to each client's anatomy, enhancing facial harmony while maintaining a natural look. Recent client transformations—highlighted across the brand's Instagram—showcase the subtle yet striking outcomes from expertly placed fillers, further solidifying Beauty Factory LV's reputation as a go-to for natural refinement. Botox Beyond Beauty: TMJ & Jaw Slimming Treatments In addition to cosmetic enhancements, Beauty Factory LV is also offering Botox for TMJ relief and jaw slimming. This innovative, non-invasive treatment helps reduce jaw tension while subtly refining the lower face—merging wellness and aesthetics in a seamless experience. About Beauty Factory LV Beauty Factory LV is a boutique medical aesthetics studio based in Las Vegas, specializing in advanced, non-surgical cosmetic treatments that blend science, luxury, and artistry. Known for delivering elite-level care in a serene, client-first environment, the studio continues to raise the bar in modern beauty. For media inquiries, appointments, or before-and-after galleries, follow Beauty Factory LV on Instagram or Name - Judy Schuler, CFO Number - +1 702-352-3560 E-mail - [email protected] To view the source version of this press release, please visit
